Reddit Posts
Mentions
I got so excited when I saw the callouts for OBAI, and realized it wasn't OABI. Dang!
Add $OABI with 4 partner drugs presentations in ASCO conference. Three poster presentations and one fast oral presentation of good phase 2 trial results.
Wouldn't we all like to know!? I'm invested heavily with 35k shares of OABI. I got in early, but I see this climbing to at least $5 EOY.
Correct, ASCO upcoming and they have 4 presentations planned by partners, abstracts already posted. 3 poster presentations and 1 fast oral presentation, which is a big deal in ASCO and for OABI. To watch closely in ASCO: AbbVie — etentamig (BCMA bispecific for multiple myeloma) And Merck KGaA — M9140 / Precemtabart tocentecan Cheering them on :D they are doing good job!
Good job man! +40% more from the time you posted. OABI rules, and i genuinely like the company and management
Anybody else on OABI? It's doubled for me in the past month and up 10% today. Nothing exciting, but strong institutional ownership and increased guidance recently.
No pennies I can think of (other than OABI). My bet is on FIG, ONDS, and CELH for upside potential (but they're not pennies).
Going to say it again...holding OABI long. Up 33% since I mentioned it a few days ago.
Fundamentals look great on OABI and OSG. I just bought for long in all three of my accounts.
Bro, finally found someone with wherewithal to go with OABI :D Q1 call was big success, not only in revenue beat of 2.5x, but on partners progressing with drug trials. Its already rated highly by analysts, but i think they will rerate it even higher.
I'm buying OABI for a long today.
Tbh probably only OABI with that potential, trading at ~1.45/share, strong buy from all analysts and 12month avg forecast is ~7 usd. Most conservative is 3 usd. Waiting for good news on q1 earnings call
Ok, I'm applying some Warren Buffett style balance sheet analysis to all of these. I looked at the 2023 numbers and put in the work so that you don't have to: Cash vs. Debt: OABI, SUP, [GFP.TO](http://GFP.TO), DATA.L, MEIP, and III all have more cash or cash equivalents than debt. Debt to Equity ratio: OABI, [GFP.TO](http://GFP.TO) were the only two to pass this with less debt than equity. In fairness, many large companies (KO comes to mind) also fail this metric. DATA.L kind of epically failed this metric, though - 7.517 - yikes! Preferred stock: OABI, PNG.V, [GFP.TO](http://GFP.TO), DATA.L, MEIP, III, and GCI all passed this benchmark by having 0 preferred stock. Retained Earning Growth (I looked at the last two years. Any negative values in the current year resulted in a negative number regardless of negative status of previous year to stay consistent with Buffett's rule of never considering a company with negative RE): DATA.L was the only company with positive RE. Treasury stock: GTN, DATA.L, III, and GCI all had positive treasury stock (a good proxy for buybacks). Conclusion: None of the recommendations have balance sheets that point to growth *and* company health at a fair P/E. DATA.L gets the closest, but with a pretty dismal debt-to-equity ratio (very high P/E), maybe slightly offset by a comfortable cash-to-debt ratio.
Check out OABI. It’s a real co with a massive future embedded royalty stream as new antibody therapies reach approval in a highly diversified pool of drugs.
Not SABS relate but still biotech- are you following OABI by chance?
GRTX & OABI both with high upside [https://finance.yahoo.com/news/2-strong-buy-penny-stocks-145352555.html](https://finance.yahoo.com/news/2-strong-buy-penny-stocks-145352555.html)
$GRTX and $OABI both are sub $5 and have strong buy ratings from multiple analysts atm, and have double digit price targets. Imo definitely worth looking into